Mercury Laboratories Ltd
Incorporated in 1962, Mercury Laboratories
Ltd manufactures and exports Pharmaceutical items of gynec and pediatrics
- Market Cap ₹ 105 Cr.
- Current Price ₹ 875
- High / Low ₹ 1,303 / 535
- Stock P/E 25.6
- Book Value ₹ 398
- Dividend Yield 0.40 %
- ROCE 16.0 %
- ROE 12.9 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 7.75% over past five years.
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
26.76 | 33.46 | 41.45 | 41.19 | 47.51 | 48.02 | 51.86 | 55.52 | 57.27 | 68.60 | 57.92 | 75.33 | 77.62 | |
23.61 | 29.63 | 35.08 | 35.40 | 41.04 | 41.30 | 47.44 | 49.79 | 51.10 | 59.01 | 50.92 | 66.76 | 70.21 | |
Operating Profit | 3.15 | 3.83 | 6.37 | 5.79 | 6.47 | 6.72 | 4.42 | 5.73 | 6.17 | 9.59 | 7.00 | 8.57 | 7.41 |
OPM % | 11.77% | 11.45% | 15.37% | 14.06% | 13.62% | 13.99% | 8.52% | 10.32% | 10.77% | 13.98% | 12.09% | 11.38% | 9.55% |
0.81 | 0.72 | 0.79 | 1.12 | 0.78 | 0.35 | 0.42 | 1.04 | 0.85 | 0.88 | 0.94 | 1.77 | 1.17 | |
Interest | 0.33 | 0.41 | 1.47 | 1.12 | 1.13 | 0.89 | 0.91 | 1.09 | 0.82 | 0.64 | 0.45 | 0.36 | 0.39 |
Depreciation | 0.30 | 0.32 | 0.89 | 1.18 | 1.18 | 1.29 | 1.47 | 1.63 | 1.87 | 1.92 | 2.45 | 2.48 | 2.73 |
Profit before tax | 3.33 | 3.82 | 4.80 | 4.61 | 4.94 | 4.89 | 2.46 | 4.05 | 4.33 | 7.91 | 5.04 | 7.50 | 5.46 |
Tax % | 30.63% | 33.51% | 32.71% | 27.98% | 20.45% | 44.79% | 17.89% | 29.88% | 25.40% | 32.49% | 29.17% | 25.47% | |
2.31 | 2.54 | 3.22 | 3.31 | 3.92 | 2.70 | 2.01 | 2.84 | 3.23 | 5.34 | 3.56 | 5.58 | 4.12 | |
EPS in Rs | 19.25 | 21.17 | 26.83 | 27.58 | 32.67 | 22.50 | 16.75 | 23.67 | 26.92 | 44.50 | 29.67 | 46.50 | 34.32 |
Dividend Payout % | 7.79% | 7.09% | 5.59% | 5.44% | 4.59% | 6.67% | 8.96% | 6.34% | 7.43% | 7.87% | 11.80% | 7.53% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 8% |
3 Years: | 10% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 23% |
3 Years: | 20% |
TTM: | -32% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | 4% |
1 Year: | 40% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 12% |
3 Years: | 12% |
Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
Reserves | 8.86 | 11.19 | 14.21 | 16.94 | 20.65 | 23.27 | 25.15 | 27.77 | 30.78 | 35.69 | 39.11 | 44.43 | 46.50 |
3.26 | 8.63 | 11.24 | 8.88 | 7.37 | 7.44 | 9.76 | 9.56 | 7.19 | 7.10 | 5.99 | 5.83 | 6.10 | |
9.43 | 11.86 | 13.56 | 15.50 | 17.30 | 19.23 | 15.59 | 18.76 | 17.13 | 21.38 | 16.14 | 16.12 | 20.75 | |
Total Liabilities | 22.75 | 32.88 | 40.21 | 42.52 | 46.52 | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 67.58 | 74.55 |
4.47 | 17.89 | 19.48 | 19.48 | 18.57 | 18.39 | 20.78 | 24.39 | 23.66 | 26.36 | 25.82 | 24.26 | 24.85 | |
CWIP | 2.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.23 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
16.16 | 14.98 | 20.72 | 23.03 | 27.94 | 32.34 | 30.67 | 32.89 | 32.63 | 39.00 | 36.61 | 43.18 | 49.46 | |
Total Assets | 22.75 | 32.88 | 40.21 | 42.52 | 46.52 | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 67.58 | 74.55 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.56 | 6.95 | 3.47 | 3.49 | -0.10 | 1.92 | 4.97 | 5.22 | 5.49 | 8.21 | 5.19 | 2.45 | |
-2.62 | -11.63 | -2.48 | -1.54 | -0.28 | -1.50 | -3.68 | -4.99 | -1.14 | -4.62 | -1.89 | -1.06 | |
0.38 | 5.20 | -1.04 | -2.12 | 0.47 | -0.25 | 1.07 | -2.54 | -3.33 | -1.24 | -1.23 | -1.01 | |
Net Cash Flow | -0.68 | 0.52 | -0.05 | -0.18 | 0.09 | 0.17 | 2.36 | -2.31 | 1.02 | 2.36 | 2.07 | 0.38 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 84.98 | 67.31 | 104.70 | 107.84 | 103.02 | 133.25 | 103.60 | 126.82 | 115.61 | 119.93 | 105.49 | 103.55 |
Inventory Days | 148.55 | 89.52 | 72.20 | 93.92 | 115.50 | 137.30 | 119.80 | 93.95 | 78.44 | 60.42 | 104.59 | 82.82 |
Days Payable | 115.57 | 152.83 | 135.37 | 159.39 | 136.34 | 186.56 | 138.65 | 161.71 | 120.01 | 137.94 | 105.98 | 76.58 |
Cash Conversion Cycle | 117.95 | 4.00 | 41.53 | 42.37 | 82.19 | 83.99 | 84.75 | 59.05 | 74.04 | 42.41 | 104.10 | 109.79 |
Working Capital Days | 85.66 | 29.34 | 33.90 | 44.22 | 75.52 | 102.84 | 90.58 | 88.75 | 88.78 | 75.02 | 98.50 | 103.35 |
ROCE % | 28.65% | 24.64% | 25.68% | 21.35% | 21.59% | 18.91% | 9.82% | 13.77% | 13.26% | 20.56% | 11.83% | 15.98% |
Documents
Announcements
-
Compliance Certificate Pursuant To Regulation 40(9) Of SEBI (LODR) Regulations, 2015
18 Apr - Compliance Certificate pursuant to Regulation 40(9) of SEBI(LODR) Regulations, 2015 for the financial year ended on March 31, 2024
- Compliance Certificate Pursuant To Reg 7(3) Of SEBI(LODR) Reg, 2015 For The Period Ended On 31St March, 2024 10 Apr
-
Announcement under Regulation 30 (LODR)-Change in Management
8 Apr - Under Reg. 30 of SEBI(LODR), Regulations, 2015 for Resignation of Mr. Mahendra Patel- General Manager Production
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate under Reg 74(5) SEBI(DP) Regulations, 2018 for the quarter ended on March 31, 2024
- Closure of Trading Window 22 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2007
from bse
-
Financial Year 2006
from bse
-
Financial Year 2005
from bse
Product Categories:[1]
Analgesic, Anti-inflammatory, Anti-pyretic, Anthelmintic, Antibiotic, Anti-coagulant,
Anti- platelet, Bleeding agents, Anti-fungal, Anti-hypertensive drugs, Anti malarial drugs, Cardiovascular System, Central Nervous System, Eye, Gastro-intestinal system, Hypoglycemic (Anti-diabetic), Multivitamin, Protein supplement, Respiratory System, Anti- allergic, Steroids, Urinary system, Uterine stimulant, Tablets, Oral Liquids, Small Volume Parenterals, Eye/Ear Drops